ArticleInternational journal of clinical and experimental pathology2018
GRP94 overexpression as an indicator of unfavorable outcomes in breast cancer patients.
Article in International journal of clinical and experimental pathology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 9 citations in OpenAlex.
- Transcription profiling of feline mammary carcinomas and derived cell lines reveals biomarkers and drug targets associated with metabolic and cell cycle pathways.Scientific reports · 2022Article
- Article
- Clinicopathologic and Prognostic Association of GRP94 Expression in Colorectal Cancer with Synchronous and Metachronous Metastases.International journal of molecular sciences · 2021Article
- Cell Surface GRP94 as a Novel Emerging Therapeutic Target for Monoclonal Antibody Cancer Therapy.Cells · 2021Review
- Plasma HSP90AA1 Predicts the Risk of Breast Cancer Onset and Distant Metastasis.Frontiers in cell and developmental biology · 2021Article
- Heat shock proteins as biomarkers of lung cancer.Cancer biology & therapy · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsThis study aimed to examine the heat shock protein Hsp90 family protein (GRP94) expression in breast cancer tissues and its correlation with clinicopathologic features, including the survival of patients with breast cancer.
methodsGRP94 mRNA expression was examined in normal breast and breast cancer tissues using real-time PCR. We also analyzed GRP94 protein expression with immunohistochemistry in 139 breast cancer patients whose ages ranged from 29 to 83 years (median =53 years). On evaluation of cytoplasmic GRP94 immunostaining, cases with a score of ≥ or ≤ six were regarded as having high or low GRP94 expression, respectively. The relationship between GRP94 expression levels and the clinical features of breast cancer were also analyzed.
resultsGRP94 mRNA expression was markedly greater in breast cancer tissues than that in normal breast tissues (P=0.0027). Immunohistochemical analysis revealed increased GRP94 protein expression in the cytoplasm of breast cancer cells, which did not positively correlate with age, tumor size classification, lymph node metastasis classification, clinical stage, or estrogen receptor expression in breast cancer patients, but did negatively correlate with progesterone receptor expression (P=0.032). Furthermore, patients with breast cancer tissue that expressed high GRP94 had a significantly shorter survival time than did patients with a low GRP94 expression (P<0.001). A multivariate analysis suggested that the level of GRP94 expression was an independent prognostic indicator (P<0.001) for the survival of patients with breast cancer.
conclusionHigh GRP94 expression levels were found to be an independent and unfavorable prognostic indicator of breast cancer survival.
Indexed as
Identifiers
31938432PMC6958070W3005995163What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.